Detection of MRD as indicated in the R3 region. A representative profile of a B-ALL patient presenting the status of triple positive cells detected in R3 region viz. OAcSGP+CD10+CD19+ or OAcSGP+CD34+CD19+ at the diagnosis is shown in PB (a) and BM (d). After the completion of 5 weeks of treatment, the BM sample first received (as per protocol) is compared with PB. The MRD (%) of these samples is shown in PB (b) and BM (e) and MRD during CR is shown in PB (c) and BM (f). Similarly, the representative profile of a T-ALL patient shows the percentage of OAcSGP+CD7+CD3+ cells at diagnosis in PB (g) and BM (j) respectively. MRD (%) in PB and BM is shown in (h, k) after 5 weeks of treatment and (i, l) during CR. PB and BM from B-ALL patient and T-ALL patient are abbreviated as PBB-ALL, BMB-ALL, PBT-ALL and BMT-ALL respectively.
Chowdhury et al. BMC Cancer 2008 8:40 doi:10.1186/1471-2407-8-40